Author｜YY 01 Focus on the ADC signals The discussion at the 2025 European Society for Medical Oncology (ESMO) annual meeting once again centered on antibody-drug conjugates (ADCs). After over a decade of clinical accumulation, ADCs are gradually moving from treatment for metastatic and advanced tumors into earlier stages of disease. At this year’s conference, AstraZeneca … Read more
Wu Ni | Author You Yi | Editor In October, Hansoh Pharmaceutical licensed the overseas rights of its self-developed ADC drug targeting CDH17 to Roche. This gastrointestinal tumor target was also a hot topic at this year’s AACR conference, where over ten related ADC drugs were showcased, with nine from Chinese pharmaceutical companies. Industry insiders … Read more
Recently, Genmab quietly removed another ADC—GEN1160 (targeting CD70) from its clinical list, citing only one reason: “slow enrollment of participants.” This follows the announcement in September to abandon the PTK7 project GEN1107, marking the second “vessel” lost from the same $1.8 billion acquisition. As of now, the three clinical “tickets” sold to Genmab by ProfoundBio … Read more
*For reference by medical professionals only Compiled by | Da Gao Ge According to global cancer statistics, the incidence of female cancers is on a continuous rise, particularly with breast cancer and ovarian cancer showing significant rates and disease burden. In the clinical diagnosis and treatment of these diseases, how to break through the efficacy … Read more
Following antibody-drug conjugates (ADCs), a new drug form known as “Degrader-Antibody Conjugate” (DAC) is gaining attention in the field of oncology and other diseases due to its unique “targeted protein degradation” mechanism. 1 What is DAC?DAC, short for Degrader-Antibody Conjugate, is an innovative drug conjugation technology. It cleverly combines the targeting specificity of monoclonal antibodies … Read more
Recently, the expert team at our hospital’s Gynecological Oncology Center successfully utilized a 3D printed individualized navigation template to guide the Large Segment Implant Radiation Therapy (HIBT) technique, precisely treating a patient with a large and complex metastatic lesion in the sacral region due to uterine sarcoma. This innovative application, which integrates cutting-edge guidance technology … Read more